👀 Ones to watch: The MOST undervalued shares to buy right nowSee Undervalued Shares

Alliance Boots says benefits from working with Walgreen

Published 15/05/2014, 13:07

LONDON (Reuters) - Alliance Boots [ABN.UL] said it had seen more benefits than expected so far from its partnership with U.S. drugstore operator Walgreen Co, and reported an 18.5 percent rise in underlying attributable profit.

Walgreen bought a 45 percent stake in Alliance Boots in 2012, with an option to buy the rest in 2015.

Alliance Boots, which runs Europe's largest pharmacy chain, reported sales for the year to March 31 rose 4.3 percent to 23.4 billion pounds ). Underlying profit was 840 million pounds.

"Our joint synergy programme with Walgreen is increasingly providing us with significant financial benefits," Alliance Boots said in a statement. "While still at an early stage, we are pleased with the overall progress of the programme, total synergies achieved to date (are) tracking ahead of target."

Deerfield, Illinois-based Walgreens reported a lower-than-expected profit for the quarter ended Feb. 28 but said it expected a bigger boost this year from its partnership with Alliance Boots.

Alliance Boots said particularly good progress had been made with a joint venture established with Walgreens to lead global relationships with pharmaceutical and other suppliers. It is also working on a joint own-brand sourcing programme in Asia and rolling out selected Boots products in Walgreens stores.

Alliance Boots said it expected the trading environment to remain challenging as European governments seek to curb healthcare spending and it faces a slow recovery in the UK, but it hopes for some improvement in the latter part of the year.

It reiterated its desire to pursue acquisitions in Latin America and China after it agreed to buy Grupo Casa Saba SAB de CV's pharmacy networks in Mexico and Chile.

Stefano Pessina, the Italian billionaire chairman of Alliance Boots, declined to comment on a report that Walgreen is under pressure from a group of shareholders to consider relocating to Europe to gain tax benefits.

($1 = 0.5960 British Pounds)

(Reporting by Emma Thomasson; editing by Kate Holton and Keiron Henderson)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.